Financial Performance - The company has not achieved profitability since its listing[4]. - The company's operating revenue for 2022 was CNY 362.51 million, representing a year-on-year increase of 15.95% compared to CNY 312.64 million in 2021[22]. - The net profit attributable to shareholders of the listed company decreased by 17.34% to CNY 20.06 million in 2022 from CNY 24.27 million in 2021[22]. - The net profit after deducting non-recurring gains and losses increased by 178.10% to CNY 15.20 million in 2022, driven by an 87.40% increase in international business revenue[23]. - The basic earnings per share for 2022 was CNY 0.08, down 11.11% from CNY 0.09 in 2021[23]. - The weighted average return on net assets decreased by 0.46 percentage points to 2.09% in 2022 from 2.55% in 2021[23]. - The net cash flow from operating activities for 2022 was CNY 52.04 million, down 20.64% from CNY 65.57 million in 2021[22]. - The company reported a decrease in operating profit by 29.99% to CNY 15.07 million, reflecting challenges in cost management[107]. - The gross margin improved to 40%, up from 35% in the previous year, reflecting better cost management and pricing strategies[162]. Research and Development - Research and development expenses accounted for 10.66% of operating revenue in 2022, a decrease of 5.74 percentage points from 16.4% in 2021[23]. - The company achieved a total R&D investment of ¥38,638,841.30 in the current year, a decrease of 24.62% compared to ¥51,257,251.58 in the previous year[77]. - The total R&D investment accounted for 10.66% of the operating revenue, down from 16.40% in the previous year, reflecting a decline of 5.74 percentage points[77]. - The company has applied for a total of 124 patents by the end of 2022, including 63 invention patents, and has been granted 77 patents, with 24 being invention patents[75]. - The company is currently conducting comprehensive iterative tests on welding parameters and fixtures for inertial friction welding, indicating an advancement in innovation capabilities[73]. Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future plans and strategies[6]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures in providing guarantees[7]. - The company has maintained compliance with relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[151]. Market Position and Strategy - The company is positioned in the midstream of the aviation industry chain, supplying critical components directly to aircraft engine manufacturers[49]. - The company has established a robust supply chain management system, ensuring quality and cost-effectiveness in procurement from qualified suppliers[54]. - The company is actively involved in national-level aerospace engine research projects, contributing to the development of domestic commercial aircraft engines[49]. - The company has successfully developed compressor blades for nearly 160 types of engines, including LEAP, GE90, and Trent1000, indicating strong market presence in the aviation engine sector[66]. - The company is focusing on high-performance manufacturing processes to enhance the efficiency and precision of difficult-to-machine materials like titanium and high-temperature alloys[70]. Environmental and Social Responsibility - The company invested 6.52 million yuan in environmental protection during the reporting period[195]. - The company has established a mechanism for environmental protection and is classified as a key pollutant discharge unit[196]. - Actual emissions of particulate matter were 0.0556 tons per year, well below the approved total of 0.3476 tons per year[196]. - The company achieved zero discharge of production wastewater through comprehensive treatment processes[198]. - The company actively participates in social responsibility initiatives, aligning with national poverty alleviation policies[194]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 25% driven by new product launches and market expansion[163]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[161]. - The company aims to enhance its production capacity and improve delivery rates while focusing on quality assurance and employee capability development[149]. - The company plans to continue expanding its international business despite potential geopolitical risks affecting operations[106]. - Future guidance indicates a focus on sustainable growth and profitability, with specific targets set for the upcoming fiscal year[159].

投资者关系活动记录表 证券代码：688510 证券简称：航亚科技 无锡航亚科技股份有限公司 | --- | --- | --- | --- | --- | |----------|-----------------------------------------------------------------------------|-------------------------------------------|-----------------------|--------------------------------| | 活动类别 | ■特定对象调研 \n□媒体采访 ■业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 | □其他 | □分析师会议 | （请文字说明其他活动内容） | | | 安信基金 | 王渊锋 百年保险 | 李兴宇 | 北信瑞丰 石 础 | | | 创金合信 | 李 晗 德邦基金 | 杜彩雯 | 鼎萨投资 岳永明 | | | 东吴人寿 | 冯佳怡 东吴证券 | 钱佳兴 | 固禾基金 文 雅 | | | 光大保德信 魏晓雪 | 光大证券 | | 冷 昊 海南儋石 魏 博 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥87,798,842.50, representing a year-on-year increase of 10.15%[3] - The net profit attributable to shareholders for Q3 2022 was ¥1,257,373.97, a significant increase of 119.06% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥733,678.75, showing a remarkable increase of 256.43% year-on-year[3] - Basic earnings per share for Q3 2022 were ¥0.0049, reflecting a 119.06% increase compared to the previous year[4] - Total operating revenue for the first three quarters of 2022 reached ¥249,602,670.26, an increase of 18.1% compared to ¥211,187,593.40 in the same period of 2021[18] - Total operating costs for the first three quarters of 2022 were ¥233,792,846.19, up from ¥206,995,488.99, reflecting an increase of 12.9%[18] - Net profit for the third quarter of 2022 was ¥7,817,221.08, a decrease of 29.9% from ¥11,047,187.80 in the same quarter of 2021[19] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥0.0339, down from ¥0.0428 in the same quarter of 2021[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,386,455,463.07, marking a 1.71% increase from the end of the previous year[4] - Total current assets as of September 30, 2022, amount to ¥724,698,704.67, a decrease from ¥837,357,580.85 at the end of 2021[15] - Total liabilities as of the end of the third quarter of 2022 amounted to ¥398,775,530.27, an increase of 11.6% from ¥357,394,276.27 at the end of the previous year[17] - Total equity attributable to shareholders of the parent company decreased to ¥943,561,782.31 from ¥960,628,936.13, a decline of 1.8%[17] - Non-current assets total ¥661,756,758.40, up from ¥525,737,667.94[15] Cash Flow - The company reported a cash flow from operating activities of -¥1,973,178.38, indicating a negative cash flow situation[3] - Cash inflow from operating activities for the first three quarters of 2022 was CNY 231,885,879.34, a significant increase from CNY 138,937,449.14 in the same period of 2021, representing a growth of approximately 67%[21] - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 1,973,178.38, an improvement compared to negative CNY 42,771,793.04 in the first three quarters of 2021[21] - Cash outflow from investing activities in the first three quarters of 2022 was CNY 185,571,307.23, a decrease from CNY 366,645,747.70 in the same period of 2021, indicating a reduction of about 49%[22] - The net cash flow from investing activities for the first three quarters of 2022 was negative CNY 155,359,803.88, an improvement from negative CNY 271,549,329.37 in the first three quarters of 2021[22] - Cash inflow from financing activities for the first three quarters of 2022 was CNY 35,750,300.00, down from CNY 119,268,000.00 in the same period of 2021[22] - The net cash flow from financing activities for the first three quarters of 2022 was negative CNY 22,630,827.87, compared to positive CNY 65,457,298.19 in the first three quarters of 2021[22] - The total cash and cash equivalents at the end of the third quarter of 2022 amounted to CNY 305,428,289.92, an increase from CNY 208,106,354.57 at the end of the same period in 2021[22] Research and Development - Research and development expenses totaled ¥9,077,761.48 for the quarter, a decrease of 34.18% compared to the same period last year[4] - The proportion of R&D expenses to operating revenue was 10.34%, down from 12.02% in the previous year, indicating a strategic reduction in R&D spending[4] - Research and development expenses for the first three quarters of 2022 were ¥30,012,140.48, down 20.5% from ¥37,865,819.61 in the same period of 2021[18] - The company plans to control the proportion of R&D projects to manage expenses more effectively, leading to a temporary reduction in R&D investment[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,505[11] - The largest shareholder, Yan Qi, holds 37,317,391 shares, representing 14.44% of total shares[11] Strategic Outlook - The company has not disclosed any significant new strategies or product developments during the reporting period[13] - The company plans to enhance market expansion strategies and invest in new product development to drive future growth[20]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,803,827.76, representing a 23.07% increase compared to ¥131,478,096.87 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 28.40% to ¥7,513,733.01 from ¥10,494,085.73 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 36.30% to ¥6,532,086.58 from ¥4,792,276.02 in the previous year[19]. - The net cash flow from operating activities improved by 49.15%, reaching -¥15,087,064.22 compared to -¥29,668,740.52 in the previous year[19]. - The total assets of the company increased by 7.16% to ¥1,352,489,797.95 from ¥1,262,093,477.29 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 0.84% to ¥942,304,408.34 from ¥950,312,031.55 at the end of the previous year[19]. - Basic earnings per share decreased by 25.00% to CNY 0.03 compared to the same period last year[20]. - The comprehensive gross margin for the reporting period was 28.26%, a decrease of 7.37 percentage points year-on-year, primarily due to increased quality costs from small-batch production of trial products[58]. - The company reported a total comprehensive income of ¥7,513,733.01 for H1 2022, compared to a loss of ¥617,223.98 in H1 2021[173]. Research and Development - R&D expenditure as a percentage of operating revenue decreased by 5.37 percentage points to 12.94%[20]. - The total R&D investment for the reporting period was ¥20,934,379, a decrease of 13.04% compared to ¥24,074,859.84 in the same period last year[49]. - The company conducts R&D primarily through independent initiatives, focusing on synchronous design and product process design to meet customer requirements[42][43]. - The R&D process includes multiple stages, such as trial production and pilot batch phases, ensuring compliance with design specifications and process stability[44]. - The number of R&D personnel decreased to 65, accounting for 15.05% of the total workforce, down from 21.97% in the previous year[55]. - The average salary of R&D personnel increased to 11.09 million RMB, compared to 10.93 million RMB in the previous year[55]. - The company has applied for a total of 112 patents, including 58 invention patents, and has authorized 73 patents, with 21 being invention patents[46]. Market and Industry Outlook - The company anticipates a steady increase in demand for aviation engine components, with a projected compound annual growth rate of 4.0% in global passenger traffic from 2021 to 2040[27]. - The domestic aviation market is expected to see a total delivery of 15,000 aviation engines over the next 20 years, with a market value of approximately USD 260 billion[27]. - The company is positioned to benefit from national policies promoting centralized procurement of high-value medical consumables, which is expected to enhance market demand and concentration among leading enterprises[31]. Production and Operations - The company maintains a direct sales model, focusing on core strategic customers and requiring quality system certifications to supply products[36]. - The company employs a production model based on sales orders, ensuring strict adherence to established production standards and processes[40]. - The company is enhancing production efficiency and product quality through the continuous advancement of digital factory construction and data-driven process improvements[40][41]. - The company is currently developing several projects, including the GE90 high-pressure compressor blade forging project, with a total investment of ¥1,000,000 and cumulative investment of ¥824,000[52]. - The company has delivered 9 products for the Changjiang series engine cold-end key components project, which has a total investment of ¥900,000 and a cumulative investment of ¥421,000[52]. Financial Position and Assets - The company's total assets decreased from CNY 1,363,095,248.79 to CNY 1,352,489,797.95, a decrease of about 0.8%[155]. - Total current assets decreased from CNY 837,357,580.85 to CNY 727,131,878.33, a decline of approximately 13.2%[153]. - Cash and cash equivalents decreased from CNY 501,289,698.24 to CNY 352,932,550.05, a decrease of about 29.6%[153]. - The company’s total equity decreased to CNY 958,350,424.96 from CNY 974,808,162.83 in the previous period[158]. - The company’s total liabilities increased from CNY 357,394,276.27 to CNY 365,730,577.20, a rise of about 2.4%[155]. Shareholder and Governance - The company held a shareholders' meeting on May 18, 2022, where several resolutions were passed, including the approval of the 2021 annual financial report and the election of new board members[97]. - The company appointed Ding Li as the new deputy general manager during the board meeting on April 26, 2022[102]. - The company has undergone a board and supervisory committee reshuffle, with several new members elected on May 18, 2022[101]. - The company has committed to various promises regarding shareholding intentions and reduction intentions, with no violations reported[112]. - The company has a lock-up period of 36 months for shares held by major shareholders, starting from the listing date[145]. Risks and Challenges - The company faces risks related to high customer concentration, with 87.52% of revenue from aviation-related business and 99.14% of aviation revenue from the top five customers[70]. - The company faces risks from increased domestic competition in the aerospace engine component manufacturing sector due to potential market entry by new players[74]. - The company is addressing challenges in meeting customer demand due to production capacity constraints and delays caused by the pandemic[60]. Environmental and Compliance - The company does not fall under the category of key pollutant discharge units and has implemented measures for zero discharge in wastewater treatment[108]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[108]. - The company has not reported any measures taken to reduce carbon emissions during the reporting period[109].

Financial Performance - The net profit attributable to ordinary shareholders for 2021 was RMB 24,271,104.15, with a proposed cash dividend of RMB 1 per 10 shares[6]. - As of December 31, 2021, the company's distributable profits amounted to RMB 110,364,632.53, with no profit distribution in 2020[6]. - The total number of shares for dividend distribution is 258,382,608, leading to a total cash dividend payout of RMB 25,838,260.80 (including tax)[6]. - The company's operating revenue for 2021 was approximately CNY 312.64 million, representing a year-over-year increase of 3.82% compared to CNY 301.12 million in 2020[22]. - The net profit attributable to shareholders decreased by 59.48% to CNY 24.27 million from CNY 59.90 million in the previous year[22]. - The basic and diluted earnings per share fell by 70.97% to CNY 0.09, down from CNY 0.31 in 2020[23]. - The net profit after deducting non-recurring gains and losses dropped by 89.6% to CNY 5.47 million compared to CNY 52.55 million in 2020[22]. - The company's total assets increased by 12.58% to CNY 1.36 billion from CNY 1.21 billion in 2020[22]. - The weighted average return on equity decreased by 11.2 percentage points to 2.55% from 13.75% in 2020[23]. - The net assets attributable to shareholders increased by 2.21% to CNY 960.63 million from CNY 939.82 million in 2020[22]. - The overall gross profit margin decreased to 31.49%, down 13.71 percentage points from the previous year[75]. - The net profit attributable to the parent company was 24.27 million RMB, a decline of 59.48% year-on-year[79]. Research and Development - Research and development expenses accounted for 16.4% of operating revenue, an increase of 6.14 percentage points from 10.26% in 2020[23]. - R&D investment totaled ¥51,257,251.58, representing a 65.95% increase year-on-year, with R&D expenses accounting for 16.4% of operating revenue, up from 10.26%[54][55]. - The number of R&D personnel increased to 99, accounting for 23% of the total workforce, up from 21% in the previous year[63]. - R&D personnel compensation totaled 2,281.27 million RMB, with an average salary of 23.04 million RMB, reflecting an increase from 20.10 million RMB in the prior year[63]. - The company has applied for a total of 110 patents, including 57 invention patents, with 23 new patent applications during the reporting period[51]. Operational Challenges - The company faced challenges due to the ongoing impact of the pandemic, changes in exchange rates, and increased costs related to product delivery and raw materials[23]. - The decline in profit was primarily due to increased R&D investment, higher costs in domestic aviation business, and the impact of medical procurement policies[33]. - The company faces risks from increased competition in the aviation engine parts manufacturing sector due to potential new entrants[76]. - Fluctuations in the USD/RMB exchange rate could impact the company's performance, as foreign sales accounted for 28.94% of total revenue[77]. Market Outlook - The Chinese aviation market is projected to receive 9,084 aircraft over the next 20 years, valued at approximately 1.4 trillion USD, indicating strong long-term demand for aviation engine components[36]. - The market for aviation engines in China is expected to deliver a total of 15,000 units over the next 20 years, with a market value of 260 billion USD[36]. - The orthopedic implant market in China is projected to reach 50.5 billion yuan by 2023, with a compound annual growth rate of 14.2% from 2019 to 2023[39]. - The company is positioned as a midstream supplier in the aviation industry chain, primarily providing finished components[41]. Strategic Initiatives - The company signed a strategic cooperation agreement with China Aviation Engine Corporation on January 29, 2021, to establish a long-term partnership[44]. - The company plans to invest 83,237.40 million RMB in expanding the capacity of key components for aircraft engines, with 6,968.14 million RMB already invested in the reporting period[114]. - The company aims to increase its actual supply share to over 50% from 35% in the partnership with Safran for blade procurement, with delivery volumes expected to return to pre-pandemic levels by 2022[123]. - The company plans to enhance production efficiency and quality management, focusing on strategic customer needs and new product development[129]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Tianye[5]. - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[4]. - The company has established a governance structure that operates effectively in accordance with relevant laws and regulations, enhancing the fairness and rationality of board decisions[134]. - The company has not encountered any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[134]. - The company has implemented a robust supplier management system to foster long-term partnerships based on mutual benefit and quality assurance[187]. Social Responsibility - The company donated materials worth 0.42 million yuan for pandemic relief and 9.6 million yuan to support rural revitalization efforts in Sanmenxia, Henan Province[180]. - The company actively participates in social responsibility initiatives, including donations and support for community welfare during the COVID-19 pandemic[172]. - The company has established a comprehensive environmental management system, including regulations for hazardous waste management and pollution control[177]. Employee and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.2764 million RMB[149]. - The company has a structured approach to determining the remuneration of senior management based on performance assessments and company profitability[149]. - The company has seen a change in the financial director position due to personal reasons, with Huang Qin being appointed following a job adjustment[150]. - The company has maintained a stable management team with no significant changes in shareholding or remuneration during the reporting period[139].

Financial Performance - The net profit attributable to ordinary shareholders for 2021 was RMB 24,271,104.15, with a proposed cash dividend of RMB 1 per 10 shares[6]. - As of December 31, 2021, the company's distributable profits amounted to RMB 110,364,632.53, with no profit distribution in 2020[6]. - The total number of shares for dividend distribution is 258,382,608, leading to a total proposed cash dividend of RMB 25,838,260.80 (including tax)[6]. - The company's operating revenue for 2021 was approximately ¥312.64 million, representing a year-over-year increase of 3.82% compared to ¥301.12 million in 2020[22]. - The net profit attributable to shareholders decreased by 59.48% to ¥24.27 million from ¥59.90 million in the previous year[22]. - The basic and diluted earnings per share fell by 70.97% to ¥0.09 from ¥0.31 in 2020[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses dropped by 89.6% to ¥5.47 million from ¥52.55 million in 2020[22]. - Operating profit decreased to 21.53 million yuan, down 68.44% compared to the previous year[33]. - The company reported a total revenue of 10,120 million RMB for the year, with a net profit of 3,108 million RMB, indicating a significant decline compared to the previous year[60]. Operational Risks and Challenges - The company has outlined various operational risks and corresponding countermeasures in the report[4]. - The company has not yet achieved profitability since its listing[4]. - The company faced challenges due to the ongoing impact of the pandemic, changes in exchange rates, and increased costs related to raw materials and external procurement[23]. - The company is exposed to risks related to quality control and raw material price fluctuations, which could adversely affect profitability[71]. - The company anticipates increased competition in the aviation engine component manufacturing sector due to potential market entry by new players[72]. Research and Development - Research and development expenses accounted for 16.4% of operating revenue, an increase of 6.14 percentage points from 10.26% in 2020[23]. - R&D investment totaled approximately ¥51.26 million in 2021, a significant increase of 65.95% year-on-year, representing 16.4% of total revenue[54][55]. - The number of R&D personnel increased to 99, representing 23% of the total workforce, up from 21% in the previous year[63]. - The total compensation for R&D personnel rose to 2,281.27 million RMB, with an average salary of 23.04 million RMB, compared to 20.10 million RMB last year[63]. - The company is focusing on research and development of new technologies to enhance product offerings and improve market competitiveness[129]. Strategic Partnerships and Collaborations - The company signed a strategic cooperation agreement with China Aviation Engine Corporation on January 29, 2021, to establish a long-term partnership[44]. - The company has established stable partnerships with major clients in the aviation engine and medical device sectors, ensuring ongoing business growth[65]. - The company aims to increase its international business share from 35% to over 50% in the supply of blades to Safran, with blade delivery volumes expected to return to pre-pandemic levels by 2022[111]. Market Outlook and Expansion - The Chinese aviation market is expected to receive 9,084 aircraft over the next 20 years, valued at approximately 1.4 trillion USD[36]. - The demand for aviation engine components in China is projected to reach 15,000 units over the next 20 years, with a market value of 260 billion USD[36]. - The orthopedic implant market in China is expected to reach 50.5 billion yuan by 2023, with a compound annual growth rate of 14.2% from 2019 to 2023[39]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[132]. Corporate Governance and Management - The company emphasizes a strong governance structure, ensuring fair decision-making and compliance with legal requirements[170]. - The company has a structured decision-making process for remuneration, involving the compensation and assessment committee and the board of directors[137]. - The company has a diverse board with members holding positions in various other organizations, enhancing its governance and strategic oversight[134]. - The company held three shareholder meetings during the reporting period, with all resolutions legally valid and properly disclosed[125]. Environmental and Social Responsibility - The company achieved zero wastewater discharge through its internal treatment processes, ensuring compliance with environmental standards[164]. - The company donated materials worth 0.42 million yuan for pandemic relief and 9.6 million yuan for rural revitalization efforts in Sanmenxia, Henan Province[168]. - The company actively participates in social responsibility initiatives, including donations and support for community welfare during the COVID-19 pandemic[160]. Future Commitments and Strategies - The company plans to invest 100 million in R&D over the next two years to drive innovation and improve product offerings[132]. - The company is committed to enhancing ESG practices and transparency in its operations, aligning with regulatory requirements[160]. - The company has outlined its strategy for market expansion and potential mergers and acquisitions in its future plans[189].

Financial Performance - The company's operating revenue for Q1 2022 was ¥61,813,276.31, representing a year-over-year increase of 5.64%[4] - The net profit attributable to shareholders decreased by 27.48% to ¥1,928,475.31, while the net profit after deducting non-recurring gains and losses fell by 41.91% to ¥1,218,286.64[4] - Total revenue for Q1 2022 was CNY 61,813,276.31, an increase of 5.3% compared to CNY 58,512,400.79 in Q1 2021[16] - Net profit for Q1 2022 was CNY 1,838,787.44, a decrease of 28.3% from CNY 2,564,275.38 in Q1 2021[17] - Operating profit for Q1 2022 was CNY 2,144,860.18, down 24.2% from CNY 2,829,185.24 in Q1 2021[16] - Basic earnings per share for Q1 2022 were CNY 0.0075, a decrease from CNY 0.0103 in Q1 2021[17] Cash Flow - The net cash flow from operating activities was negative at -¥37,136,425.67, an increase in outflow of 24.8% compared to the previous year[4] - Cash flow from operating activities for Q1 2022 was negative CNY 37,136,425.67, worsening from negative CNY 29,756,181.28 in Q1 2021[20] - Cash flow from investing activities for Q1 2022 was negative CNY 80,847,003.13, compared to negative CNY 43,492,833.50 in Q1 2021[21] - Cash flow from financing activities for Q1 2022 was positive CNY 11,674,813.81, down from CNY 45,124,414.88 in Q1 2021[21] - The ending cash and cash equivalents balance for Q1 2022 was CNY 376,775,133.46, down from CNY 428,887,050.65 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,380,825,670.50, reflecting a 1.3% increase from the previous year[5] - Current assets decreased from RMB 837,357,580.85 at the end of 2021 to RMB 750,238,889.88, a decline of about 10.4%[11] - Cash and cash equivalents were RMB 386,956,363.94, down from RMB 501,289,698.24, indicating a decrease of approximately 22.8%[12] - The company's inventory increased from RMB 97,697,958.57 to RMB 124,862,113.99, representing a rise of about 27.8%[12] - Total liabilities rose from RMB 357,394,276.27 to RMB 373,285,910.54, an increase of approximately 4.4%[13] - The company's equity attributable to shareholders increased slightly from RMB 960,628,936.13 to RMB 962,557,411.44, a growth of about 0.2%[13] - The company’s non-current assets totaled RMB 630,586,780.62, up from RMB 525,737,667.94, reflecting an increase of approximately 19.9%[12] - The company’s short-term borrowings increased from RMB 38,216,572.92 to RMB 50,885,472.92, a rise of about 33.1%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,863[8] - The top shareholder, Yan Qi, holds 14.44% of the shares, totaling 37,317,391 shares[8] Research and Development - Research and development expenses totaled ¥7,364,057.35, accounting for 11.91% of operating revenue, an increase of 1.16 percentage points[5] - Research and development expenses for Q1 2022 were CNY 7,364,057.35, a decrease of 14.3% compared to CNY 8,591,652.85 in Q1 2021[16] Strategic Initiatives - The company plans to continue focusing on product structure adjustments to improve profitability and address the decline in gross margin[6] - The company signed a long-term supply agreement with a French client, increasing the average share of LEAP series blade products from 35% to at least 50% starting January 1, 2023[10] Accounts Receivable - The company reported a significant increase in accounts receivable, with RMB 188,419,523.86 compared to RMB 189,979,014.95, indicating a slight decrease of about 0.8%[11]

2021 年第三季度报告 证券代码：688510 证券简称：航亚科技 无锡航亚科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | 年初至报告期末 | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 79,709,496.53 | 20.56 | 211,187,593.40 | -4.29 ...

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 131,478,096.87, a decrease of 14.92% compared to RMB 154,533,617.24 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 10,494,085.73, down 64.12% from RMB 29,247,438.95 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 4,792,276.02, a decline of 83.49% compared to RMB 29,034,194.67 in the same period last year[19]. - The net cash flow from operating activities was negative RMB 29,668,740.52, compared to negative RMB 2,608,119.71 in the previous year, representing a decrease of 1,037.55%[19]. - The company's basic earnings per share decreased by 73.09% to CNY 0.0406 compared to the same period last year[20]. - Operating revenue decreased by 14.92%, primarily due to a 27.37% decline in international business and delays in domestic aviation engine deliveries[20]. - The weighted average return on net assets decreased by 5.85 percentage points to 1.11%[20]. - The net cash flow from operating activities dropped by 1,037.55% due to increased procurement payments and reduced cash recovery from sales[20]. Research and Development - R&D investment accounted for 18.31% of operating revenue, an increase of 7.94 percentage points compared to the previous year[20]. - The company focuses on independent research and development, with key projects involving synchronous design for critical components in collaboration with major engine design institutions[33]. - The company has applied for a total of 101 patents, including 46 invention patents, and has authorized 64 patents, with 13 being invention patents[56]. - Research and development expenses increased by 50.20% from the previous period, totaling approximately ¥24.07 million, which represents 18.31% of total revenue[60]. - The company has developed advanced core technologies, including precision forging near-net-shape technology and adaptive polishing technology for complex surfaces[50]. Market Position and Strategy - The aviation engine industry is experiencing significant growth, with China projected to become the largest civil aircraft market in the next 20 years, creating opportunities for domestic manufacturers[38]. - The orthopedic implant market in China is growing rapidly, with significant potential for domestic manufacturers to replace imported brands, particularly in spine and joint segments[43]. - The company is positioned to benefit from the increasing international outsourcing market for aviation engine components due to its recognized product quality and high production efficiency[41]. - The company is focusing on strategic customers and high-end markets to maintain its position in the domestic market while advancing its international strategy[83]. - The company is actively expanding its product range and enhancing its technological capabilities to support the development of advanced aerospace components[66]. Production and Operations - The company has established a direct sales model, focusing on core strategic customers and requiring quality certifications to supply products[28]. - The production model is based on a make-to-order approach, ensuring strict adherence to quality standards and customer requirements[31]. - The company has implemented a digital factory construction to enhance production efficiency and product quality, achieving automated rapid mold change based on accumulated production data[32]. - The company has established three business segments: compressor blades, rotating parts, and medical orthopedics, supported by a complete engineering and industrialization platform[36]. - The company emphasizes quality management, implementing a solid quality management system and regular training to enhance quality awareness among employees[37]. Financial Position and Investments - The total assets at the end of the reporting period were RMB 1,262,093,477.29, reflecting a growth of 4.24% from RMB 1,210,801,572.29 at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were RMB 950,312,031.55, an increase of 1.12% from RMB 939,817,945.82 at the end of the previous year[19]. - The company has invested a total of 8,480 million RMB in various projects, with 1,522 million RMB invested in the current period and a cumulative investment of 3,086 million RMB[66]. - The company has made a new equity investment of ¥105 million during the reporting period[99]. - The company has established Guizhou Hangya Technology Co., Ltd. with a total investment of RMB 300 million, where the company invested RMB 210 million and has completed an initial investment of RMB 105 million[142]. Corporate Governance and Compliance - The company appointed Huang Qin as the new Chief Financial Officer and Wei Zhe as the new Secretary of the Board, following the resignation of the previous CFO due to health reasons and the Secretary's reassignment[111]. - The company has committed to maintaining a lock-up period for major shareholders and core technical personnel for 36 months post-IPO, with additional restrictions on share sales for 2 years thereafter[121]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[118]. - The company has made commitments regarding the reduction of related party transactions, as per the announcements on the Shanghai Stock Exchange[123]. - The company has no significant litigation or arbitration matters during the reporting period[138].

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[19]. - The net profit for the first half of 2021 was RMB 15 million, which is a 25% increase compared to the same period last year[19]. - The company's operating revenue for the first half of 2021 was approximately ¥131.48 million, a decrease of 14.92% compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 64.12% to approximately ¥10.49 million, while the net profit after deducting non-recurring gains and losses fell by 83.49% to approximately ¥4.79 million[20]. - Basic earnings per share dropped by 73.09% to ¥0.0406, and diluted earnings per share also decreased by the same percentage[21]. - The total profit for the first half of 2021 was RMB 10,846,940.00, down from RMB 32,461,686.38 in the same period last year[171]. - The company achieved operating revenue of 131.48 million yuan, a decrease of 14.92% year-on-year[80]. - Operating profit was 9.91 million yuan, down 69.89% compared to the same period last year[80]. - The company reported a net cash flow from financing activities of CNY 50.93 million, an increase of 176.78% due to increased borrowings[95]. Research and Development - The company has allocated RMB 10 million for research and development in the upcoming fiscal year, focusing on innovative technologies[19]. - The company's R&D investment as a percentage of operating revenue increased by 7.94 percentage points to 18.31%[21]. - R&D expenses increased significantly by 50.20% from the previous period, totaling approximately ¥24.07 million, which represents 18.31% of the operating revenue[61]. - The company has applied for a total of 101 patents, including 46 invention patents, and has authorized 64 patents, with 13 being invention patents as of June 30, 2021[57]. - The company has developed key technologies such as adaptive polishing for blade edges and reverse design for complex molds, enhancing production efficiency and product quality[52]. Market Strategy and Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2022[19]. - Future guidance estimates a revenue growth of 25% for the full year 2021, projecting total revenue to reach RMB 400 million[19]. - The company is focusing on strategic customers and high-end markets to maintain its position in the domestic market while advancing its international strategy[84]. - The company is actively pursuing new product development initiatives to drive future growth[123]. Operational Efficiency - The company has improved production efficiency by implementing a digital factory and utilizing production data for continuous process improvement, particularly in the production of compressor blades and orthopedic implants[33]. - The company is actively improving operational efficiency, particularly in reducing process costs and shortening production cycles[84]. - The company has established a digital manufacturing system that integrates automation and quality control, enhancing production efficiency and earning recognition as a "demonstration smart workshop" in Jiangsu Province[74]. Risk Management - Risk factors include potential supply chain disruptions, which the company is actively monitoring and managing[19]. - The company is addressing risks related to technology development, talent retention, and quality control, which are critical for maintaining competitive advantage in the aerospace and medical sectors[86][87][88]. - The company is focusing on enhancing its risk management strategies to safeguard against market volatility and economic uncertainties[186]. Environmental and Social Responsibility - The company has implemented a zero discharge policy for wastewater, treating it through an internal facility before reuse in production[118]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[118]. - The company has confirmed that it does not fall under the category of heavily polluting enterprises and has implemented effective waste management practices[118]. Shareholder and Governance - The company has a commitment from its major shareholders and management to maintain shareholding stability for a period of 36 months post-IPO[121]. - The company did not propose any profit distribution or capital reserve fund transfer for the first half of 2021, with no dividends or stock bonuses planned[115]. - The company has made long-term commitments regarding profit distribution policies, as disclosed on the Shanghai Stock Exchange[123]. - The company has made specific commitments regarding the reduction of shares held by directors and senior management, adhering to the Shanghai Stock Exchange rules[135]. Industry Trends - The aviation engine industry is experiencing significant growth, with emerging markets driving demand for air travel, particularly in China, which is projected to become the largest civil aircraft market in the next 20 years[39]. - The orthopedic implant market in China is experiencing rapid growth, with a significant opportunity for domestic brands to increase their market share, particularly in spinal and joint implants where the localization rate remains low[44].